09:15 AM EDT, 03/24/2025 (MT Newswires) -- PROCEPT BioRobotics ( PRCT ) said Monday that an independent trial showed its aquablation therapy provided similar symptom relief, with superior ejaculatory function and continence preservation compared to laser enucleation for treating large prostates.

The company said the study, which treated 186 men, showed positive results for the three-month primary safety and efficacy endpoints, with long-term follow-up planned for up to five years.

The aquablation therapy arm also reported a 0% transfusion rate, highlighting the therapy's safety and effectiveness in minimizing bleeding risks, it added.